Sanofi - Aventis Groupe: Press Release: Dupixent (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old

Dupixent (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old 68% of children

Related Keywords

Japan ,Paris ,France General ,France ,Eva Schaefer Jansen ,Corentine Driancourt ,Felix Lauscher ,Sharon Chen ,Mirna Chehade ,Vesna Tosic ,Nathalie Pham ,Sally Bain ,Priya Nanduri ,Regeneron Pharmaceuticals Inc ,Twitter ,Regeneron Genetics Center ,Drug Administration ,Dupilumab Development Program ,Nasdaq ,Exchange Commission ,European Union ,Mount Sinai Center ,Icahn School Of Medicine ,Euronext ,United European Gastroenterology ,Sinai Center ,Eosinophilic Disorders ,Icahn School ,These Phase ,About Eosinophilic ,Dupixent Pediatric Eosinophilic Esophagitis ,Regeneron Genetics ,Private Securities Litigation Reform Act ,Statement Regarding Forward Looking ,Forward Looking Statements ,Regeneron Pharmaceuticals ,Product Candidates ,Sanofi ,Eventis ,Roupe ,Dress ,Release ,Dupixent ,Dupilumab ,Gate ,Breaking ,Hase ,Data ,Resented ,Eek ,022 ,Howed ,Significant ,Istological ,Remission ,Eosinophilic ,Esophagitis ,Children ,Sea ,